SUNNYVALE, CA, May 23 /PRNewswire/ — New ‘Plus’ version of the test adds a third genetic target to improve detection of future SARS-CoV-2 variants
Cepheid today announced that it has received the CE marking for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for the qualitative detection of viruses that transmit COVID-19, influenza A, influenza B, and respiratory infections. syncytial virus (RSV) from a single patient sample. An additional new version of the test provides a third genetic target for SARS-CoV-2 detection in order to meet the challenge of future virus mutations. The Xpert Xpress CoV-2 / Flu / RSV plus is designed for use on one of more than 35,000 Cepheid GeneXpert® systems worldwide with results available after approximately 36 minutes.
Many types of the virus that causes COVID-19 have been documented worldwide during the pandemic. Viruses are constantly changing through mutations, and new types of viruses can be expected to emerge over time. The addition of a third genetic target to the Plus version of Cepheid’s CoV-2/Flu/RSV assay provides broader coverage to mitigate potential effects of viral genetic drift in the future.
“During this time of year, health care providers can encounter a range of viral infections whose symptoms overlap with COVID-19, including influenza A, influenza B, and respiratory syncytial virus. Rapid and accurate testing to detect current and future variants of COVID-19 and viruses Influenza is getting more and more important,” explained Dr. David Piersing, MD, PhD, chief of medicine and technology at Cepheid. “By being able to take a single sample and run a single highly sensitive, multiplexed test that detects and identifies all four viruses, actionable results can be provided to help us make better decisions at the forefront of our healthcare systems.”
Delivery of the Xpert Xpress CoV-2 / Flu / RSV plus to countries that accept CE marked products is expected to begin this month.
visit https://www.cepheid.com/ar For more information, videos and publications.
Information about Sevid
Cepheid, headquartered in Sunnyvale, California, is a leading provider of molecular diagnostics. Cepheid is dedicated to improving healthcare by developing, manufacturing and marketing accurate, easy-to-use molecular testing systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions provide facilities of all sizes a better way to perform cutting-edge molecular diagnostic testing for organisms and genetic diseases. With its expertise in molecular biology, the company focuses on applications that urgently require accurate, rapid and actionable test results, such as: treating infectious diseases and cancer. For more information, see http://www.cepheid.com.
For Cepheid press inquiries:
Drew Peterson [email protected]
Stocks on the radar:Strabag.
Precious metals phyllo
Veloro was established in Vienna in March 2011 as an independent precious metals trading company and is one of the leading investment in high quality precious metals in Europe. The family business, in which industrialist Max Turner acquired a stake in 2019, looks after both private and institutional clients.
>> Visit 65 other partners boerse-social.com/partner
More current OTS news here
“Total coffee aficionado. Travel buff. Music ninja. Bacon nerd. Beeraholic.”